Software - Application
Compare Stocks
5 / 10Stock Comparison
YAAS vs CANG vs AUTL vs BZUN vs JD
Revenue, margins, valuation, and 5-year total return — side by side.
Auto - Dealerships
Biotechnology
Specialty Retail
Specialty Retail
YAAS vs CANG vs AUTL vs BZUN vs JD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Software - Application | Auto - Dealerships | Biotechnology | Specialty Retail | Specialty Retail |
| Market Cap | $419K | $250M | $410M | $165M | $46.46B |
| Revenue (TTM) | $1M | $3.46B | $51M | $9.77B | $1.30T |
| Net Income (TTM) | $-4M | $-178M | $-225M | $-204M | $32.20B |
| Gross Margin | 57.2% | 13.6% | -309.4% | 49.2% | 12.7% |
| Operating Margin | -248.7% | 7.3% | -8.6% | -0.5% | 1.3% |
| Forward P/E | — | 5.7x | — | 1.0x | 1.4x |
| Total Debt | $2M | $170M | $53M | $2.52B | $89.77B |
| Cash & Equiv. | $18K | $1.29B | $227M | $1.64B | $108.35B |
YAAS vs CANG vs AUTL vs BZUN vs JD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 24 | May 26 | Return |
|---|---|---|---|
| Youxin Technology L… (YAAS) | 100 | 0.3 | -99.7% |
| Cango Inc. (CANG) | 100 | 24.4 | -75.6% |
| Autolus Therapeutic… (AUTL) | 100 | 68.3 | -31.7% |
| Baozun Inc. (BZUN) | 100 | 101.5 | +1.5% |
| JD.com, Inc. (JD) | 100 | 87.1 | -12.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: YAAS vs CANG vs AUTL vs BZUN vs JD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
YAAS lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, CANG doesn't own a clear edge in any measured category.
AUTL is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 496.0%, EPS growth 27.5%, 3Y rev CAGR 88.7%
- 496.0% revenue growth vs CANG's -52.7%
- +30.5% vs YAAS's -99.2%
BZUN ranks third and is worth considering specifically for value.
- Lower P/E (1.0x vs 1.4x)
JD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 1.06, yield 2.6%
- 48.7% 10Y total return vs CANG's -44.9%
- Lower volatility, beta 1.06, Low D/E 28.7%, current ratio 1.29x
- Beta 1.06, yield 2.6%, current ratio 1.29x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 496.0% revenue growth vs CANG's -52.7% | |
| Value | Lower P/E (1.0x vs 1.4x) | |
| Quality / Margins | 2.5% margin vs AUTL's -439.7% | |
| Stability / Safety | Beta 1.06 vs CANG's 2.25 | |
| Dividends | 2.6% yield, 1-year raise streak, vs BZUN's 0.1%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +30.5% vs YAAS's -99.2% | |
| Efficiency (ROA) | 4.6% ROA vs YAAS's -65.8% |
YAAS vs CANG vs AUTL vs BZUN vs JD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
YAAS vs CANG vs AUTL vs BZUN vs JD — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CANG leads in 2 of 6 categories
JD leads 2 • BZUN leads 1 • YAAS leads 0 • AUTL leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
CANG leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JD is the larger business by revenue, generating $1.30T annually — 961355.9x YAAS's $1M. JD is the more profitable business, keeping 2.5% of every revenue dollar as net income compared to AUTL's -4.4%. On growth, CANG holds the edge at +58.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1M | $3.5B | $51M | $9.8B | $1.30T |
| EBITDAEarnings before interest/tax | -$3M | $333M | -$427M | -$4M | $23.8B |
| Net IncomeAfter-tax profit | -$4M | -$178M | -$225M | -$204M | $32.2B |
| Free Cash FlowCash after capex | -$4M | $0 | -$278M | $0 | $9.1B |
| Gross MarginGross profit ÷ Revenue | +57.2% | +13.6% | -3.1% | +49.2% | +12.7% |
| Operating MarginEBIT ÷ Revenue | -2.5% | +7.3% | -8.6% | -0.5% | +1.3% |
| Net MarginNet income ÷ Revenue | -2.7% | -5.2% | -4.4% | -2.1% | +2.5% |
| FCF MarginFCF ÷ Revenue | -2.8% | -154.0% | -5.4% | -1.1% | +0.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +21.2% | +58.3% | — | +4.8% | +14.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +97.8% | +3.6% | +3.2% | -29.2% | -56.3% |
Valuation Metrics
BZUN leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
At 5.7x trailing earnings, CANG trades at a 26% valuation discount to JD's 7.6x P/E. On an enterprise value basis, CANG's 3.1x EV/EBITDA is more attractive than BZUN's 15.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $419,114 | $250M | $410M | $165M | $46.5B |
| Enterprise ValueMkt cap + debt − cash | $2M | $85M | $235M | $294M | $43.7B |
| Trailing P/EPrice ÷ TTM EPS | -0.33x | 5.66x | -1.84x | -6.08x | 7.64x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 0.95x | 1.43x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 0.29x |
| EV / EBITDAEnterprise value multiple | — | 3.13x | — | 15.40x | 6.40x |
| Price / SalesMarket cap ÷ Revenue | 0.80x | 2.12x | 40.47x | 0.12x | 0.27x |
| Price / BookPrice ÷ Book value/share | — | 0.42x | 0.96x | 0.19x | 1.01x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 7.14x |
Profitability & Efficiency
JD leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
JD delivers a 10.5% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-109 for YAAS. CANG carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to BZUN's 0.44x. On the Piotroski fundamental quality scale (0–9), BZUN scores 6/9 vs YAAS's 2/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -109.2% | -4.1% | -84.7% | -3.7% | +10.5% |
| ROA (TTM)Return on assets | -65.8% | -2.3% | -34.0% | -2.1% | +4.6% |
| ROICReturn on invested capital | — | +4.6% | -2.0% | -1.3% | +9.9% |
| ROCEReturn on capital employed | — | +4.5% | -45.9% | -1.7% | +10.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 | 5 | 6 | 6 |
| Debt / EquityFinancial leverage | — | 0.04x | 0.12x | 0.44x | 0.29x |
| Net DebtTotal debt minus cash | $1M | -$1.1B | -$175M | $879M | -$18.6B |
| Cash & Equiv.Liquid assets | $18,372 | $1.3B | $227M | $1.6B | $108.3B |
| Total DebtShort + long-term debt | $2M | $170M | $53M | $2.5B | $89.8B |
| Interest CoverageEBIT ÷ Interest expense | — | -1.87x | -25.98x | -0.78x | 12.85x |
Total Returns (Dividends Reinvested)
CANG leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CANG five years ago would be worth $8,579 today (with dividends reinvested), compared to $34 for YAAS. Over the past 12 months, AUTL leads with a +30.5% total return vs YAAS's -99.2%. The 3-year compound annual growth rate (CAGR) favors CANG at 0.4% vs YAAS's -85.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -34.4% | -62.0% | -14.2% | -1.8% | +5.7% |
| 1-Year ReturnPast 12 months | -99.2% | -73.7% | +30.5% | -15.9% | -7.7% |
| 3-Year ReturnCumulative with dividends | -99.7% | +1.2% | -14.6% | -40.4% | -8.2% |
| 5-Year ReturnCumulative with dividends | -99.7% | -14.2% | -70.1% | -91.6% | -53.8% |
| 10-Year ReturnCumulative with dividends | -99.7% | -44.9% | -93.6% | -49.3% | +48.7% |
| CAGR (3Y)Annualised 3-year return | -85.0% | +0.4% | -5.1% | -15.8% | -2.8% |
Risk & Volatility
JD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
JD is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than CANG's 2.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JD currently trades 79.3% from its 52-week high vs YAAS's 0.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.60x | 2.25x | 1.95x | 1.48x | 1.06x |
| 52-Week HighHighest price in past year | $560.00 | $2.88 | $2.70 | $4.88 | $38.08 |
| 52-Week LowLowest price in past year | $0.75 | $0.33 | $1.15 | $2.07 | $24.51 |
| % of 52W HighCurrent price vs 52-week peak | +0.2% | +18.6% | +59.4% | +56.6% | +79.3% |
| RSI (14)Momentum oscillator 0–100 | 49.7 | 58.6 | 64.3 | 53.8 | 58.0 |
| Avg Volume (50D)Average daily shares traded | 3.6M | 1.3M | 1.6M | 376K | 10.1M |
Analyst Outlook
Evenly matched — CANG and JD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CANG as "Buy", AUTL as "Buy", BZUN as "Buy", JD as "Buy". Consensus price targets imply 459.2% upside for CANG (target: $3) vs 8.8% for JD (target: $33). JD is the only dividend payer here at 2.61% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $3.00 | $8.87 | $5.35 | $32.86 |
| # AnalystsCovering analysts | — | 2 | 14 | 13 | 45 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +0.1% | +2.6% |
| Dividend StreakConsecutive years of raises | — | 5 | — | 0 | 1 |
| Dividend / ShareAnnual DPS | — | — | — | $0.02 | $5.37 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.3% | 0.0% | +8.5% | +8.2% |
CANG leads in 2 of 6 categories (Income & Cash Flow, Total Returns). JD leads in 2 (Profitability & Efficiency, Risk & Volatility). 1 tied.
YAAS vs CANG vs AUTL vs BZUN vs JD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is YAAS or CANG or AUTL or BZUN or JD a better buy right now?
For growth investors, Autolus Therapeutics plc (AUTL) is the stronger pick with 496.
0% revenue growth year-over-year, versus -52. 7% for Cango Inc. (CANG). Cango Inc. (CANG) offers the better valuation at 5. 7x trailing P/E, making it the more compelling value choice. Analysts rate Cango Inc. (CANG) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — YAAS or CANG or AUTL or BZUN or JD?
On trailing P/E, Cango Inc.
(CANG) is the cheapest at 5. 7x versus JD. com, Inc. at 7. 6x. On forward P/E, Baozun Inc. is actually cheaper at 1. 0x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — YAAS or CANG or AUTL or BZUN or JD?
Over the past 5 years, Cango Inc.
(CANG) delivered a total return of -14. 2%, compared to -99. 7% for Youxin Technology Ltd (YAAS). Over 10 years, the gap is even starker: JD returned +48. 7% versus YAAS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — YAAS or CANG or AUTL or BZUN or JD?
By beta (market sensitivity over 5 years), JD.
com, Inc. (JD) is the lower-risk stock at 1. 06β versus Cango Inc. 's 2. 25β — meaning CANG is approximately 112% more volatile than JD relative to the S&P 500. On balance sheet safety, Cango Inc. (CANG) carries a lower debt/equity ratio of 4% versus 44% for Baozun Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — YAAS or CANG or AUTL or BZUN or JD?
By revenue growth (latest reported year), Autolus Therapeutics plc (AUTL) is pulling ahead at 496.
0% versus -52. 7% for Cango Inc. (CANG). On earnings-per-share growth, the picture is similar: Cango Inc. grew EPS 960. 0% year-over-year, compared to 27. 5% for Autolus Therapeutics plc. Over a 3-year CAGR, AUTL leads at 88. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — YAAS or CANG or AUTL or BZUN or JD?
Cango Inc.
(CANG) is the more profitable company, earning 37. 3% net margin versus -21. 8% for Autolus Therapeutics plc — meaning it keeps 37. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CANG leads at 22. 2% versus -23. 9% for AUTL. At the gross margin level — before operating expenses — YAAS leads at 65. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is YAAS or CANG or AUTL or BZUN or JD more undervalued right now?
On forward earnings alone, Baozun Inc.
(BZUN) trades at 1. 0x forward P/E versus 1. 4x for JD. com, Inc. — 0. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CANG: 459. 2% to $3. 00.
08Which pays a better dividend — YAAS or CANG or AUTL or BZUN or JD?
In this comparison, JD (2.
6% yield) pays a dividend. YAAS, CANG, AUTL, BZUN do not pay a meaningful dividend and should not be held primarily for income.
09Is YAAS or CANG or AUTL or BZUN or JD better for a retirement portfolio?
For long-horizon retirement investors, JD.
com, Inc. (JD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 06), 2. 6% yield). Cango Inc. (CANG) carries a higher beta of 2. 25 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JD: +48. 7%, CANG: -44. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between YAAS and CANG and AUTL and BZUN and JD?
These companies operate in different sectors (YAAS (Technology) and CANG (Consumer Cyclical) and AUTL (Healthcare) and BZUN (Consumer Cyclical) and JD (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: YAAS is a small-cap quality compounder stock; CANG is a small-cap deep-value stock; AUTL is a small-cap high-growth stock; BZUN is a small-cap quality compounder stock; JD is a mid-cap deep-value stock. JD pays a dividend while YAAS, CANG, AUTL, BZUN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.